Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Venetoclax
Drug ID BADD_D02345
Description Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566]. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022]. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax [A40022]. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022]. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion [F2130].
Indications and Usage For the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
Marketing Status Prescription
ATC Code L01XX52
DrugBank ID DB11581
KEGG ID D10679
MeSH ID C579720
PubChem ID 49846579
TTD Drug ID Not Available
NDC Product Code 68513-0566; 0074-0576; 68513-0561; 54893-0090; 68543-0576; 71796-008; 0074-0579; 68513-0576; 0074-0566; 0074-0561; 46708-920
Synonyms venetoclax | 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide | benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)- | GDC-0199 | RG-7601 | RG7601 | ABT-199 | Venclexta
Chemical Information
Molecular Formula C45H50ClN7O7S
CAS Registry Number 1257044-40-8
SMILES CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C =C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatosplenomegaly09.01.05.002; 01.09.03.0010.000533%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.001066%Not Available
Herpes zoster11.05.02.003; 23.09.03.002--
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.0030.000799%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.002398%
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.001598%
Hyperphosphataemia14.04.03.0070.001598%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.002--
Hypophosphataemia14.04.03.0010.001598%
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.000486%
Ileus07.13.01.0010.000139%
Infection11.01.08.0020.004378%Not Available
Influenza22.07.02.001; 11.05.03.0010.002931%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.0050.000799%Not Available
Laboratory test abnormal13.18.01.001--Not Available
Leukaemia16.01.03.001; 01.10.03.0010.000556%
Leukocytosis01.02.01.0020.001865%
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Localised infection11.01.08.0060.001598%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages